Search
Anacaulase
go.drugbank.com/drugs/DB17449ApprovedInvestigational[A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717] … Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes.
Nafamostat
go.drugbank.com/drugs/DB12598InvestigationalThe use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. … Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. … Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine
Pozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigational[L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalThe reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively.
Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnGrepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. … Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States
AS-8112
go.drugbank.com/drugs/DB09207ExperimentalAS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.
Categories: Dopamine D2 Receptor AntagonistsTreosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]
DAS-431 IV
go.drugbank.com/drugs/DB05432ExperimentalDAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.